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Abstract
Objectives To investigate the safety and efficacy of durable polymer
drug eluting stents (DES) and biodegradable polymer biolimus eluting
stents (biolimus-ES).
Design Network meta-analysis of randomised controlled trials.
Data sources and study selection Medline, Google Scholar, Embase,
and Cochrane Central Register of Controlled Trials (CENTRAL) database
search for randomised controlled trials comparing at least two of durable
polymer sirolimus eluting stents (sirolimus-ES) and paclitaxel eluting
stents (paclitaxel-ES), newer durable polymer everolimus eluting stents
(everolimus-ES), Endeavor and Resolute zotarolimus eluting stents
(zotarolimus-ES), and biodegradable polymer biolimus-ES.
Primary outcomes Safety (death, myocardial infarction, definite or
probable stent thrombosis) and efficacy (target lesion and target vessel
revascularisation) assessed at up to one year and beyond.
Results 60 randomised controlled trials were compared involving 63
242 patients with stable coronary artery disease or acute coronary
syndrome treated with a DES. At one year, there were no differences
in mortality among devices. Resolute and Endeavor zotarolimus-ES,
everolimus-ES, and sirolimus-ES, but not biodegradable polymer
biolimus-ES, were associated with significantly reduced odds of
myocardial infarction (by 29-34%) compared with paclitaxel-ES.
Compared with everolimus-ES, biodegradable polymer biolimus-ES
were associated with significantly increased odds of myocardial infarction
(by 29%), while Endeavor zotarolimus-ES and paclitaxel-ES were
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RESEARCHassociated with significantly increased odds of stent thrombosis. All
investigated DES were similar with regards to efficacy endpoints, except
for Endeavor zotarolimus-ES and paclitaxel-ES, which were associated
with significantly increased the odds of target lesion and target vessel
revascularisations compared with other devices. Direction of results
beyond one year did not diverge from the findings for up to one year
follow-up. Bayesian probability curves showed a gradient in the
magnitude of effect, with everolimus-ES and Resolute zotarolimus-ES
offering the highest safety profiles.
Conclusions The newer durable polymer everolimus-ES and Resolute
zotarolimus-ES and the biodegradable polymer biolimus-ES maintain
the efficacy of sirolimus-ES; however, for safety endpoints, differences
become apparent, with everolimus-ES and Resolute zotarolimus-ES
emerging as the safest stents to date.
Introduction
The first generation of coronary drug eluting stents (DES) has
considerably reduced the need for repeat revascularisation
compared with bare metal stents (BMS) and has led to their
widespread use worldwide. Concerns have emerged, however,
regarding late and very late thrombotic events, which in turn
are associated with a high rate of death and myocardial
infarction.
1 2 Such events have been attributed to incomplete
re-endothelialisation caused by drug induced inhibition of
endothelial cell proliferation, stent malapposition, accelerated
neoatherosclerosis,and,importantly,polymerinducedprolonged
vessel wall inflammation.
3
To improve the safety of first generation DES, new devices
have been developed that use either biocompatible durable
polymers combined with new metal alloys or biodegradable
polymers combined with stainless steel platforms; both have
been extensively tested in randomised controlled trials. The
second generation durable polymer everolimus eluting stent
(everolimus-ES) has been found to be safer than BMS and first
generation DES.
4-6 On the other hand, two non-inferiority trials
comparingthemostinvestigatedbiodegradablepolymerdevice,
thebiolimuselutingstent(biolimus-ES),withthefirstgeneration
sirolimus eluting stent (sirolimus-ES) have provided
contradictory results at one year,
7 8 with one trial showing
non-inferiority and the other failing to do so. Two other trials
have shown non-inferiority of biodegradable polymer
biolimus-ES compared with everolimus-ES.
9 10 None of these
trials was powered for separate safety and efficacy endpoints.
In light of these findings, the safety and efficacy of the
biodegradable polymer devices compared with first generation
paclitaxel-eluting stents (paclitaxel-ES) and sirolimus-ES, and
withsecondgenerationdurablepolymerEndeavorandResolute
zotarolimuselutingstents(zotarolimus-ES)andeverolimus-ES,
are currently unclear. We performed a comprehensive network
meta-analysis of all relevant data published and presented to
date to gain an evidence based understanding of the impact of
each of these devices compared with first generation DES and
among each other on major safety and efficacy outcomes.
Methods
Study design and endpoint selection
WecomparedthesafetyandefficacyofDEScurrentlyapproved
by the Food and Drug Administration (FDA)—that is, first and
second generation durable polymer DES and biodegradable
polymer biolimus-ES. We selected biodegradable polymer
biolimus-ES from among the different types of biodegradable
polymer stents for two reasons: they have the most robust trial
data, and all available biodegradable polymer biolimus-ES
prototypes share a stainless steel platform, similar strut
thickness, and the same abluminal biodegradable polymer
(poly-L-lactic acid) and therefore are generally considered
equivalent. We limited our analysis to biodegradable polymer
biolimus-ES as the other non-FDA approved biodegradable
polymer devices are characterised by a limited number or
absenceofcomparisonsandbydifferentstentdesigns(interms
of strut thickness, antiproliferative agents, and polymers),
resulting in a large degree of heterogeneity among existing
devices. Because of the conflicting one year outcome results,
our primary pre-specified analyses were for up to one year
follow-up, though we also analysed longer follow-ups. To
provide the most robust evidence, we included randomised
controlled trials enrolling at least 100 patients and with a
minimum follow-up of six months.
To appreciate the comparative effect of different types of DES
within their class, we did not include BMS. We included first
generation durable polymer sirolimus-ES and paclitaxel-ES;
second generation durable polymer everolimus-ES, Endeavor
zotarolimus-ES, and Resolute zotarolimus-ES; and
biodegradable polymer biolimus-ES. Prespecified safety
endpoints comprised overall mortality, myocardial infarction,
and definite or probable stent thrombosis according to the
definition criteria of the Academic Research Consortium.
11
Efficacy endpoints were target lesion and target vessel
revascularisation.
Although there were a limited number of trials comparing
biodegradable polymer biolimus-ES with first and second
generation DES that reported results beyond one year, we
additionally performed such an analysis (see appendix).
Data source and search strategy
We adhered to the PRISMA (Preferred Reporting Items for
SystematicreviewsandMeta-Analyses)statementforreporting
systematic reviews and meta-analyses in healthcare
interventions.
12 Medline, Cochrane Central Register of
Controlled Trials (CENTRAL), Google Scholar, and Embase
databases and www.tctmd.com, www.clinicaltrials.gov, www.
clinicaltrialresults.org, and www.cardiosource.com websites
were searched until 15 May 2013 for relevant randomised
controlledtrials;documentsaccessiblethroughtheFDAwebsite
were also scrutinised. The following keywords were used:
“randomised trials”, “drug-eluting stent”, “sirolimus stent”,
“paclitaxel stent”, “everolimus stent”, “zotarolimus stent”,
“Endeavor zotarolimus-stent”, “Resolute zotarolimus-stent”,
“biodegradablepolymerstent”,“bioabsorbablepolymerstent”,
“biolimus stent”. No language, date, or publication status
restrictions were imposed. For each trial, we used the most
updated or most inclusive data.
Data collection and quality assessment
Four investigators (EPN, KT, BC, MK) critically and
independently evaluated identified trials with regard to patient
population, treatment, protocol, and endpoint selection.
Divergences were resolved by consensus. Two investigators
(BC, KT) independently appraised the potential risk of bias in
trials according to the Cochrane Collaboration guidelines
(adequatesequencegeneration,allocationconcealment,blinded
adjudication of events)
12; discrepancies were resolved by
discussion with a third investigator (EPN). EK supervised the
data collection process. Trials with high or unclear risk of bias
for any of these components were regarded as trials with a high
risk of bias.
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We used network meta-analysis methods on all available
treatment comparisons to provide the most comprehensive
evidence,incorporatingdirectcomparisonswithintrialsbetween
two treatments (such as A v B) and indirect comparisons from
trials having one treatment in common (such as A v C using
trials comparing A v B and B v C).
13 Outcome analyses were
compared by odds ratios and 95% credible intervals with a
bayesian hierarchical random effects model that takes into
account multi-arm trials. We adopted the random effects rather
than the fixed effects model as the most appropriate and
conservative analysis to account for differences among trials.
Additionalsensitivityanalyseswereconductedbyrepeatingthe
main computations with the fixed effect method and by
excluding trials with high risk of bias.
To further corroborate the robustness of the data and make
probabilityinferences,wegeneratedbayesianprobabilitycurves
for each stent with sirolimus-ES as reference; rather than
focusing on a single probability value, these curves provide a
ranking of competing stent treatments with respect to overall
safety and efficacy. Median rates of safety and efficacy
outcomes, with corresponding credible intervals, were also
calculatedfromtheoriginaltrialsinthenetworkmeta-analysis.
Heterogeneity was defined as the variability of results across
trials over and above chance, with τ
2 <0.04 indicating low level
andτ
2>0.4ahighlevel.Potentialinconsistencyofthenetwork,
defined as the variability of results across the direct and indirect
evidence comparisons, was evaluated by the node split method
andtherelativebayesianPvalue,measuringagreementbetween
direct and indirect evidence for each split node.
14 Inconsistency
was additionally evaluated by inspection of the goodness of fit
of the model to the data with residual deviance; the model was
considered to provide an adequate fit when the mean of the
residual deviance was similar to the number of data points of
the model.
For outcomes beyond one year, given the variable length of
follow-up for each of these trials, we used the rate of outcome
per 100 patient years to obtain the log rate ratios of one stent
compared with another. Rates per unit of time, rather than
number of events, were deemed the most appropriate outcome
measureforlongtermanalysesastheyincorporatetheduration
of the trials, which was variable. A Poisson regression model
was fitted because this analysis explicitly exploits differences
in follow-up among studies, thus maximising precision.
15 We
assessed the extent of small study effects/publication bias by
visual inspection of funnel plots. All analyses were based on
non-informativepreviousfindingsforeffectsizesandprecision,
which yield results that are comparable with those obtained
from conventional statistical analyses. Convergence and lack
ofautocorrelationwerecheckedandconfirmed.Inthebayesian
framework, we regarded as significant results for which the
credible intervals of the odds ratios or rate ratios did not include
the unit value. Data were analysed according to the intention to
treat principle. All analyses were conducted with WinBUGS
1.4.3 (MRC Biostatistics Unit, Cambridge, UK) and MIX 2.0.
ProforMicrosoftExcel,version2.0.1.2,(BiostatXL,California,
USA).
Results
Study selection and patient population
The flow diagram of the analysis, the full electronic Medline
database search, and the inclusion/exclusion criteria and risk of
bias of the included randomised controlled trials are shown in
the appendix (fig S1, table S1, table S2). Sixty trials,
7-10 16-88
comprising 63 242 randomised patients, met the inclusion
criteriaandenteredthefinalanalysis.Table1showsinformation
on stent comparators, duration of follow-up, and investigated
populations⇓. In general, the included populations were high
risk groups, with most trials enrolling patients with stable
coronary artery disease (53.7%) and acute coronary syndromes
(46.3%). Nearly all included trials were multicentre, with a low
risk of bias. We excluded trials testing two stents eluting the
same drug but differing in their design,
89-91 trials with different
stent metal platforms,
92-96 post hoc analyses or substudies,
97-103
the BMS arm or polymer free arm of six trials with three
arms,
16 17 38 39 54 104 studies that did not report clinical outcomes,
105
and arms that did not include treatments in the network. Figure
1 shows the evidence network of direct comparisons⇓.
One year outcomes
Safety profile
A total of 46 studies (n=48 908) contributed to the analysis of
one year mortality. Second generation durable polymer DES
and biodegradable polymer biolimus-ES were associated with
mortality outcomes that did not differ significantly from those
of paclitaxel-ES and sirolimus-ES (fig 2⇓), although median
one year rates varied almost twofold, ranging from 1.80% to
3.05% (numerical gradient: Resolute zotarolimus-ES <
everolimus-ES < sirolimus-ES < biodegradable polymer
biolimus-ES<paclitaxel-ES<Endeavorzotarolimus-ES)(table
2⇓).
Forty six studies (n=51 578) contributed to the analysis of
myocardialinfarctionbyoneyear.Comparedwithpaclitaxel-ES,
allDESexceptbiodegradablepolymerbiolimus-ESsignificantly
reducedtheoddsofmyocardialinfarction,particularlyResolute
zotarolimus-ES and everolimus-ES (odds ratio 0.66 (95%
credible interval 0.46 to 0.91) and 0.67 (0.53 to 0.81),
respectively) (fig 3⇓). Compared with sirolimus-ES, the odds
of myocardial infarction were not significantly reduced by
second generation DES, although everolimus-ES and Resolute
zotarolimus-ES, unlike biodegradable polymer biolimus-ES,
showed numerical reductions (fig 3⇓). When new generation
DESwerecomparedamongeachother,biodegradablepolymer
biolimus-ES yielded a significant increase in the odds of
myocardial infarction (1.29, 1.02 to 1.69) compared with
everolimus-ES. Lowest median rates of myocardial infarction
wereobservedwithResolutezotarolimus-ESandeverolimus-ES
(table 2⇓). There was no evidence of high heterogeneity among
trials for either death (τ
2=0.007) or myocardial infarction
(τ
2=0.008) outcomes (supplementary table S3).
Compared with paclitaxel-ES and Endeavor zotarolimus-ES,
median rates of stent thrombosis were approximately halved
with everolimus-ES, Resolute zotarolimus-ES, biodegradable
polymer biolimus-ES, and sirolimus-ES (~1% v ~2.5%) (table
2⇓).Everolimus-ESprovidedsignificantreductionsoftheodds
of stent thrombosis at one year compared with paclitaxel-ES
(0.37, 0.18 to 0.65) and a numerical reduction compared with
sirolimus-ES (0.63, 0.33 to 1.06) (fig 4⇓); compared with
everolimus-ES, Endeavor zotarolimus-ES yielded a significant
increase in the odds of stent thrombosis (3.13, 1.15 to 8.89).
There was no evidence of high heterogeneity among trials for
stent thrombosis (τ
2=0.21; appendix table S3).
Efficacy profile
Forty four trials including 49 527 patients contributed to the
analysis of target lesion revascularisation at one year.
Sirolimus-ES, everolimus-ES, biodegradable polymer
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the odds of target lesion revascularisation by 46% to 87%
compared with paclitaxel-ES, and by 59% to 160% compared
with Endeavor zotarolimus-ES (fig 5⇓). Compared with
sirolimus-ES, the same devices (everolimus-ES, Resolute
zotarolimus-ES, and biodegradable polymer biolimus-ES)
showed a similar degree of efficacy, without significant
differences between them (fig 5). The median target lesion
revascularisation rate was ~3% with everolimus-ES,
biodegradablepolymerbiolimus-ES,sirolimus-ES,andResolute
zotarolimus-ES versus 5.92% with paclitaxel-ES and 7.52%
with Endeavor zotarolimus-ES (table 2).⇓
Target vessel revascularisation results at one year were
consistent with target lesion revascularisation outcomes.
Compared with sirolimus-ES, everolimus-ES, Resolute
zotarolimus-ES, and biodegradable polymer biolimus-ES
provided similar efficacy profiles, whereas Endeavor
zotarolimus-ES and paclitaxel-ES were associated with higher
odds of target vessel revascularisation (odds ratio 1.67 (95%
credible interval 1.08 to 2.58) and 1.47 (1.14 to 1.90),
respectively) (fig 6⇓). There was no evidence of high
heterogeneity among trials for both target lesion
revascularisation (τ
2= 0.13) and target vessel revascularisation
(τ
2= 0.12) outcomes (appendix table S3).
Posterior probabilities
Figure 7⇓ shows the posterior probability curves for each DES
andforeachoutcome,withsirolimus-ESasreferencetreatment.
These curves allow probability inferences associated with a
specific threshold of risk (odds ratio). Thus, compared with
sirolimus-ES,thecurvesshowaprobabilityof65%forResolute
zotarolimus-ES to reduce the odds of mortality by at least 20%
(odds ratio 0.80); a probability of 56% and 49% for Resolute
zotarolimus-ES and everolimus-ES, respectively, to reduce the
odds of myocardial infarction by at least 10% (0.90); and a
probability of 81% with everolimus-ES and 51% with Resolute
zotarolimus-ES to reduce the odds of stent thrombosis by at
least 20%.
Comparedwithsirolimus-ES,Resolutezotarolimus-ESshowed
a 30% probability to reduce target vessel revascularisation and
a 21% probability to reduce target lesion revascularisation by
at least 20% (odds ratio 0.80), which was comparable with the
17% probability seen with everolimus-ES and biodegradable
polymer biolimus-ES.
Outcomes beyond one year
Twenty four trials (n=38 097) contributed to the analysis of
follow-up after one year (table 1)⇓. As with the one year
mortality results, long term mortality with first and second
generation durable polymer DES and with biodegradable
polymer biolimus-ES did not differ significantly among the
different DES (appendix table S4).
As seen with the one year outcomes, in comparison with
paclitaxel-ES, Endeavor zotarolimus-ES, everolimus-ES, and
Resolute zotarolimus-ES (similarly to sirolimus-ES) provided
a 31-37% significant decrease in myocardial infarction.
Everolimus-ESwasassociatedwithasignificant56%reduction
of the rate of definite or probable stent thrombosis against first
generation sirolimus-ES. Again, similar to the one year
outcomes, compared with first generation paclitaxel-ES, newer
generation DES offered significantly lower rates of
revascularisation, except for Endeavor zotarolimus-ES, which
was associated with a 110% increase compared with
everolimus-ES (appendix table S4).
Overall fit of the model and additional
analyses
Evaluation of the goodness of fit for the models showed
adequate fit for the various analyses. Heterogeneity among the
trialswaslowtomoderateforalloutcomes(appendixtableS3).
Sensitivity analyses based on the fixed effect model did not
significantly change the results of the meta-analysis (appendix
table S5). Visual inspection of funnel plots did not suggest any
small study effects or publication bias (appendix figs S2A-D).
Exclusion of trials with high risk of bias (appendix table S6)
yieldedresultslargelyconsistentwiththeoverallresults.Finally,
there was no evidence of inconsistency between direct and
indirect estimates, with bayesian P values ranging from 0.06 to
1 (appendix table S7).
Discussion
This large meta-analysis, with 63 242 patients, examined the
safetyandefficacyprofileofsecondgenerationdurablepolymer
drug eluting stents (DES) and biodegradable polymer
biolimus-EScomparedwithfirstgenerationDESandwitheach
other. Second generation durable polymer everolimus-ES and
Resolutezotarolimus-ES,thefirstgenerationsirolimus-ES,and
the biodegradable polymer biolimus-ES were similar to each
other with regards to their efficacy and significantly better than
Endeavor zotarolimus-ES and paclitaxel-ES with regards to
coronary revascularisations. There was a safety gradient, with
everolimus-ESandResolutezotarolimus-ESresultinginlowest
rates of death and myocardial infarction and, conversely,
biodegradablepolymerbiolimus-ES,Endeavorzotarolimus-ES,
and paclitaxel-ES being associated with significantly increased
odds of myocardial infarction or stent thrombosis compared
with everolimus-ES.
Possibly one of our most important findings was the significant
increaseintheoddsofmyocardialinfarctionwithbiodegradable
polymer biolimus-ES compared with durable polymer
everolimus-ES. To date, biodegradable polymer biolimus-ES
have been perceived as safer than first generation sirolimus-ES
and non-inferior to second generation everolimus-ES, mainly
on the basis of results from individual trials powered only for
composite endpoints of safety and efficacy.
7 9 10 We analysed
single (instead of composite) endpoints of safety and have
provided new insights suggesting that biodegradable polymer
biolimus-ES is associated with similar (not higher) safety
compared with the first generation sirolimus-ES and with a
significantlyhigherrateofmyocardialinfarctioncomparedwith
everolimus-ES. Indeed, the second generation durable polymer
everolimus-ES and Resolute zotarolimus-ES were associated
with the most favourable safety profile compared with not only
the first generation durable polymer paclitaxel-ES but also the
secondgenerationEndeavorzotarolimus-ESandbiodegradable
polymer biolimus-ES. In a wider perspective, this study shows
that among all devices compared, the durable polymer second
generationeverolimus-ESandResolutezotarolimus-ESarethe
safest DES to date.
Our findings agree with those of two previous network
meta-analyses
4 5thatcomparedfirstandsecondgenerationDES
with bare metal stents (BMS). The current meta-analysis,
however, substantially differs from the others by incorporating
the most recent evidence from head-to-head DES comparison
trials and forming the largest DES database ever analysed, with
a total of 63 242 patients. We also included biodegradable
polymer biolimus-ES, which are used mainly in Europe and
Asia, thus providing a comprehensive overview of the most
widely used DES in current clinical practice worldwide, not
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safety and efficacy endpoints.
Although our exclusion of BMS might be perceived as a
limitation,methodologicalandconceptualreasonsdictatedsuch
a choice. For a network meta-analysis to provide the highest
degree of precision, robust direct and indirect evidence is
required. This would not have been possible if we had included
BMS as, to date, the direct comparison between biodegradable
polymer biolimus-ES and BMS is limited to a single trial,
makingindirectcomparisonsthroughthis“weak”commonlink
imprecise and meaningful conclusions difficult.
106 Moreover,
thesafetyandefficacyofdurablepolymer“limus”-EScompared
with BMS has already been clarified.
4 5 Our study differs in
design and in the number of included patients from a previous
meta-analysis of three randomised controlled trials comparing
biodegradable devices with sirolimus-ES, which found a
reduction of stent thrombosis associated with biodegradable
stents.
107 The devices pooled in the previous study under the
biodegradable group were in fact three distinct types, only one
of which is a biodegradable polymer biolimus-ES; all of them
represent differences in terms of the biodegradable polymer
used, the eluted drug, and stent strut thickness. To provide the
most robust conclusions and avoid heterogeneity that might
arise by pooling stents with different properties, we decided to
includeonlybiodegradablepolymerbiolimus-ESinthisanalysis.
Safety
ThesafetyoffirstgenerationDEShasbeenextensivelydebated.
The relatively high rates of stent thrombosis associated with
thesedevices,aphenomenonthattranslatesintoincreasedrates
of death or myocardial infarction, raised concerns regarding
their widespread use, despite the clear efficacy benefits over
BMS.
1 2 Further studies showed that the mechanisms of stent
thrombosis after DES implantation are complex, with factors
relatedtodevicedesignbeingofparamountimportance.Indeed,
the inflammation induced by the durable polymers of first
generation DES could result in delayed healing and incomplete
covering of stent struts by new and functional endothelium,
with uncovered stent struts serving as a source for future
episodes of stent thrombosis.
3 Other factors such as stent
malapposition and mechanical tissue injury caused by stent
struts during implantation, however, also play a role in stent
thrombosis.
20 New generation DES have dealt with the
limitations observed with first generation devices in different
ways; biodegradable polymer biolimus-ES use abluminal
biodegradablepolymersthatdissolvewithinsixtoninemonths,
with the residual metal platform presumably regaining a safety
profilesimilartoaBMSbeyondthistimeframe.
108Conversely,
second generation durable polymer DES have replaced first
generation polymers with more biocompatible and thinner
polymers.
109-111 Interestingly, the design improvements of the
new generation durable polymer DES have run in parallel with
a reduction of definite stent thrombosis rates, compared with
thefirstgenerationpaclitaxel-ESandsirolimus-ESinbothearly
and late and very late phases of follow-up.
4 79 Furthermore late
stent thrombosis, with everolimus-ES being the first and most
studied prototype, is reduced not only compared with first
generation DES but also with BMS, suggesting that the durable
fluoropolymerusedinthesedevicesmightbe“thromboresistant”
and more biocompatible than BMS,
4-6 in turn generating a shift
from the contention of an increased risk of stent thrombosis
with DES compared with BMS towards the converse relation.
In contrast, biodegradable polymer biolimus-ES have failed to
provide a significant reduction in one year stent thrombosis
rates compared with sirolimus-ES, with both available trials
showing a numerical advantage of sirolimus-ES.
7 8 Although
thefiveyearfollow-upofLEADERS
44—theonlyavailabletrial
withalongfollow-up—showsasignificantreductionoftheone
to five year rates of stent thrombosis compared with
sirolimus-ES,theoverallrateatfiveyearswasnotsignificantly
lower than for sirolimus-ES, pointing once more to the impact
of first year outcomes. In our analysis, the stent thrombosis
outcomes continue to favour the newer generation durable
polymer DES, particularly everolimus-ES.
Stentthrombosis,however,remainsasurrogatesafetyendpoint
and needs to be interpreted in the context of objective safety
endpoints such as death and myocardial infarction. We found
that the durable polymer DES yielded lower odds of death and
myocardial infarction compared with biodegradable polymer
biolimus-ES, with everolimus-ES reaching a significant
reduction in myocardial infarction. Of note, this finding is in
line with the results of the NEXT and COMPARE II trials,
9 10
both of which showed a numerical reduction of myocardial
infarction associated with everolimus-ES compared with
biodegradablepolymerbiolimus-ES,whichbecamesignificant
for Q-wave myocardial infarction in the latter. The advantage
with regards to myocardial infarction observed with thin strut
devicessuchaseverolimus-ESmightberelatednotonlytostent
thrombosisbutalsotolowerratesofperiproceduralmyocardial
infarction resulting from side branch jailing, which in turn for
mechanistic reasons might be more frequent with thick strut
devices.
112 Higher degrees of re-endothelialisation achievable
with these stents compared with the thick strut devices have
been shown in preclinical
113 and optical coherence tomography
studies
114 and might also play a role. Our findings on safety
among different DES should also be viewed in the context of
patients treated with DES who need to undergo non-cardiac
surgery; surgery represents one of the most common reasons
for premature discontinuation of antiplatelet therapy, which is
associated with a significant increase in mortality and major
adversecardiacevents.
115Indeed,thefavourableprofileobserved
with second generation DES might become clinically relevant
in this context, in light of recent studies suggesting the safety
of shorter overall duration of dual antiplatelet therapy (three to
six months) in patients treated with these devices.
116 117 In this
perspective, newer thin strut biodegradable polymer DES
recently introduced in the market might have the potential to
enhance safety and efficacy outcomes after percutaneous
coronary intervention (BIO-RESORT, TWENTE III
(NCT01674803) and EVOLVE II QCA (NCT01787799)).
Analyses beyond one year confirmed maintenance of the
direction of the estimates observed at one year follow-up.
Efficacy
Factors related to design, such as strut thickness, type of
antiproliferative agent, drug elution kinetics, and elution time,
as well as type of polymer, could all affect efficacy
outcomes.
118 119 We found that the new generation
everolimus-ES, biodegradable polymer biolimus-ES, Resolute
zotarolimus-ES, and the first generation sirolimus-ES were
associated with reduced rates of target lesion and target vessel
revascularisation compared with Endeavor zotarolimus-ES
and/or first generation paclitaxel-ES. Our findings therefore
confirm on a larger scale the comparable efficacy of
biodegradablepolymerbiolimus-ESandsecondgenerationDES
shown in the recent NEXT trial, powered for target lesion
revascularisation as primary endpoint.
10
Although not a new finding, in this analysis all “limus”-ES,
withtheexceptionofEndeavorzotarolimus-ES,wereassociated
with significantly lower rates of target lesion and target vessel
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6530 doi: 10.1136/bmj.f6530 (Published 6 November 2013) Page 5 of 17
RESEARCHrevascularisation than the first generation paclitaxel-ES. This
findingcouldderivefromthedifferencesinthehealingprocess
after implantation between paclitaxel and limus eluting stents.
Indeed, the toxicity caused by the long lasting presence of
paclitaxel in the vessel wall could give rise to acellular healing
process, with prolonged fibrin deposition and inflammation, as
shown in preclinical and postmortem studies.
3 120 On the other
hand, with Endeavor zotarolimus-ES, short release kinetics
could result in insufficient inhibition of neointimal hyperplasia.
Indeed, the more recently introduced Resolute zotarolimus-ES,
which has a much longer (up to 180 days) release curve of the
same antiproliferative agent, zotarolimus, is associated with a
significant reduction in target lesion and target vessel
revascularisation compared with Endeavor zotarolimus-ES.
Limitations
As with any meta-analysis, our study shares the limitations of
the original studies. Results were analysed on trial level data,
and therefore we could not assess whether all baseline
characteristics were balanced among groups (although for the
mostparttheywerebalancedwithineachrandomisedcontrolled
trial). Data for follow-up beyond a year were limited but seem
toconfirmthedirectionoftheestimatesatoneyear.Thecriteria
for inclusion of patients of this meta-analysis were broad, more
closely reflecting current practice, comprising both stable and
unstablehighriskpatients.Potentiallyheterogeneousdefinitions
of myocardial infarction used across the trials could represent
another limitation. There was no evidence of significant
statisticalinconsistencyamongtrials;heterogeneityamongtrials
was found to be moderate for stent thrombosis and low to
moderate for target lesion and target vessel revascularisation.
On the other hand, the stability of the results in the sensitivity
analyses confirms that the overall outcome effect is robust and
justified. Another aspect is the duration of dual antiplatelet
therapy (the combination of aspirin and a P2Y12 receptor
blocker),whichvariedamongthedifferenttrials.Thevariability
of dual antiplatelet therapy, however, could be less important
inthecontextofthepresentmeta-analysisgiventhatBMSwere
excluded and most trials used at least six months of dual
antiplatelet therapy (a summary of current guideline
recommendations
121 is in the appendix). Because of the limited
number of trials that assessed Resolute zotarolimus-ES, the
findings with this device should be viewed as exploratory but
certainly deserve further attention.
Despite these limitations, this network meta-analysis provides
the largest scale comparative information on the efficacy and
safety profiles of different DES in current use.
Conclusions
Biodegradable polymer biolimus-ES show a similar efficacy
and safety profile to first generation sirolimus-ES. Compared
with second generation everolimus-ES and Resolute
zotarolimus-ES, biodegradable polymer biolimus-ES again
provide similar efficacy outcomes. Safety outcomes, however,
favour both everolimus-ES and Resolute zotarolimus-ES,
suggesting that these second generation durable polymer stents
are the safest for current clinical practice.
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RESEARCHTables
Table 1 Randomised controlled trials included in network meta-analysis of safety and efficacy outcomes of first and second generation
durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents
Clinical setting (%)
Maximum
follow-up
(months) Trial design Stent comparators
Total sample
size Trial
Stable coronary artery disease/ACS
(42/58)
6 Superiority (cost
effectiveness)/single centre
SES v PES (v BMS) 525 (826) BASKET, 2005
16
Stable coronary artery disease/ACS
(35/65)
24 Superiority (cost
effectiveness)/multicentre
EES v SES (v BMS) 1549 (2314) BASKET-PROVE, 2010
17
Stable coronary artery disease 12 Parallel/multicentre ZES-E v SES 160 CATOS, 2012
18
Stable coronary artery disease 12 Non-inferiority/multicentre EES v SES 207 CIBELES, 2013
19
Stable coronary artery disease/ACS
(40/60)
24 Superiority/single centre EES v PES 1800 COMPARE, 2010-11
20 21
Stable coronary artery disease/ACS
(42/58)
12 Non-inferiority/multicentre BP-BES v EES 2707 COMPARE II, 2013
9
Stable coronary artery disease 6 Parallel/multicentre SES v PES 515 CORPAL, 2005
22
STEMI 6 Parallel/multicentre ZES-E v SES 875 CREST MI, 2011
23
Stable coronary artery disease/ACS
(42/58)
48 Superiority/multicentre SES v PES 400 DES-diabetes, 2008-11
24 25
Stable coronary artery disease/ACS
(67/33)
8 Superiority/multicentre SES v PES 153 DiabeDES, 2009
26
Stable coronary artery disease 60 Non-inferiority/multicentre ZES-E v SES 436 ENDEAVOR III, 2006-11
27 28
Stable coronary artery disease/ACS
(53/47)
60 Non-inferiority/multicentre ZES-E v PES 1548 ENDEAVOR IV, 2010-13
29 30
Stable coronary artery disease/ACS
(58/42)
12 Non-inferiority/multicentre EES v SES 300 ESSENCE-Diabetes, 2011
31
Stable coronary artery disease/ACS
(48/52)
12 Non-inferiority/multicentre EES v SES 1443 EXCELLENT, 2010
32
Stable coronary artery disease/ACS
(39/61)
36 Parallel/multicentre SES v PES 169 Hong et al, 2010
33
Stable coronary artery disease/ACS
(60/40)
9 Non-inferiority/multicentre SES v PES 250 ISAR-DIABETES, 2005
34
Stable coronary artery disease 24 Non-inferiority/multicentre SES v PES 607 ISAR-Left-Main, 2009
35
Stable coronary artery disease/ACS
(64/36)
12 Non-inferiority/multicentre ZES-R v EES 650 ISAR-Left-Main 2, 2012
36
Stable coronary artery disease/ACS
(69/31)
12 Non-inferiority/multicentre SES v PES 360 ISAR-SMART 3, 2006
37
Stable coronary artery disease/ACS
(58/42)
24 Superiority/multicentre ZES-E v SES (v polymer
free dual DES)
674 (1007) ISAR-TEST-2, 2009-10
38 39
STEMI 12 Superiority/single centre SES v PES 397 Juwana et al, 2009
40
Stable coronary artery disease 12 Parallel/single centre SES v PES 100 Kamoi et al, 2011
41
Stable coronary artery disease/ACS
(39/61)
6 Superiority/multicentre SES v PES 169 Kim et al, 2008
42
STEMI 18 Parallel/multicentre ZES-E v SES v PES 611 KOMER, 2011
43
Stable coronary artery disease/ACS
(45/55)
60 Non-inferiority/multicentre BP-BES v SES 1707 LEADERS, 2008-13
7 44
Stable coronary artery disease/ACS
(45/55)
9 Superiority/multicentre SES v PES 500 Long DES II, 2006
45
Stable coronary artery disease/ACS
(58/42)
12 Non-inferiority/multicentre EES v SES 450 LONG-DES III, 2011
46
Stable coronary artery disease/ACS
(64/36)
12 Non-inferiority/multicentre ZES-R v SES 500 LONG-DES V, 2012
47
Stable coronary artery disease/ACS
(86/14)
36 Superiority single-centre ZES-E v SES v PES 226 Naples diabetes, 2010
48
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RESEARCH(continued)
Clinical setting (%)
Maximum
follow-up
(months) Trial design Stent comparators
Total sample
size Trial
Stable coronary artery disease/ACS
(84/16)
12 Non-inferiority/multicentre BP-BES v EES 3235 NEXT, 2013
10
Stable coronary artery disease/ACS
(80/20)
9 Non-inferiority/multicentre BP-BES v PES 120 NOBORI 1-Phase 1, 2007
49
Stable coronary artery disease/ACS
(72/28)
12 Non-inferiority/multicentre BP-BES v PES 243 NOBORI 1-Phase 2, 2009
50
Stable coronary artery disease/ACS
(86/14)
36 Non-inferiority/multicentre BP-BES v SES 335 NOBORI Japan, 2012
51 52
Stable coronary artery disease/ACS
(40/60)
24 Superiority/multicentre SES v PES 205 Pan et al, 2007
53
STEMI 48 Superiority/single centre SES v PES (v BMS) 180 (270) PASEO, 2009
54
Stable coronary artery disease/ACS
(52/48)
9 Superiority/single centre SES v PES 100 Petronio et al, 2007
55
Stable coronary artery disease 12 Superiority/multicentre SES v ZES-E + SES v
ZES-R
304 PRISON III, 2013
56
STEMI 36 Superiority/multicentre SES v PES 308 PROSIT, 2008-11
57 58
Stable coronary artery disease/ACS
(55/45)
36 Superiority/multicentre ZES-E v SES 8709 PROTECT, 2012
59
Stable coronary artery disease/ACS
(9/91)
12 Non-inferiority/multicentre ZES-R v PES 400 R-CHINA RCT, 2013
60
Stable coronary artery disease/ACS
(70/30)
12 Superiority/multicentre SES v PES 1386 REALITY, 2006
61
Stable coronary artery disease/ACS
(82/18)
12 Non-inferiority/multicentre EES v SES 3197 RESET, 2011
62
Stable coronary artery disease/ACS
(29/71)
12 Parallel/single centre BP-BES v EES 200 Separham et al, 2011
66
Stable coronary artery disease/ACS
(49/51)
60 Superiority/multicentre SES v PES 1012 SIRTAX, 2005-11
67 68
Stable coronary artery disease/ACS
(45/55)
18 Superiority/multicentre SES v PES 2098 SORT OUT II, 2008
69
Stable coronary artery disease/ACS
(55/45)
36 Superiority/multicentre ZES-E v SES 2332 SORT OUT III, 2010-12
70 71
Stable coronary artery disease/ACS
(58/42)
24 Non-inferiority/multicentre EES v SES 2774 SORT OUT IV, 2012
72 73
Stable coronary artery disease/ACS
(51:49)
9 Non-inferiority/multicentre BP-BES v SES 2468 SORT OUT V, 2013
8
Stable coronary artery disease/ACS
(62/38)
60 Non-inferiority/multicentre EES v PES 300 SPIRIT II, 2006-12
74 75
Stable coronary artery disease/ACS
(80/20)
36 Non-inferiority/multicentre EES v PES 1001 SPIRIT III, 2008-11
76 77
Stable coronary artery disease/ACS
(72/28)
24 Superiority/multicentre EES v PES 3717 SPIRIT IV, 2010-11
78 79
Stable coronary artery disease/ACS
(64/36)
12 Non-inferiority/multicentre EES v PES 324 SPIRIT V, 2012
80
Stable coronary artery disease/ACS
(84/16)
36 Superiority/single centre SES v PES 202 TAXI-LATE, 2005-07
81 82
Stable coronary artery disease/ACS
(49/51)
24 Non-inferiority/single centre ZES-R v EES 1391 TWENTE, 2012-13
83 84
STEMI 12 Non-inferiority/multicentre EES v SES 625 XAMI, 2012
85
Stable coronary artery disease/ACS
(45/55)
12 Superiority (ZES-E v
PES)/non-inferiority (ZES-E v
SES)/multicentre
ZES-E v SES v PES 2645 ZEST, 2010
86
STEMI 12 Superiority/multicentre ZES-E v SES v PES 328 ZEST-AMI, 2009
87
Stable coronary artery disease/ACS
(45/55)
12 Superiority/single centre SES v PES 673 Zhang et al, 2006
88
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RESEARCH(continued)
Clinical setting (%)
Maximum
follow-up
(months) Trial design Stent comparators
Total sample
size Trial
SES=sirolimus eluting stents; PES=paclitaxel eluting stents; BMS=bare metal stent; ZES-E=Endeavor zotarolimus stent; ZES-R=Resolute zotarolimus stent;
EES=Everolimus eluting stent; BP-BES=biodegradable polymer biolimus-eluting stent; DES=drug eluting stent; ACS=acute coronary syndrome; STEMI=ST-elevation
myocardial infarction.
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RESEARCHTable 2| One year event rates with different types of drug eluting stent (DES). Numbers are rates (95% credible intervals)
ZES-R BP-BES ZES-E EES PES SES
1.80 (1.04 to 3.00) 2.48 (1.64 to 3.67) 3.05 (1.96 to 4.62) 2.27 (1.59 to 3.17) 2.68 (1.88 to 3.75) 2.45 (1.86 to 3.14) Death
2.28 (1.52 to 3.39) 3.00 (2.07 to 4.27) 2.47 (1.67 to 3.58) 2.32 (1.68 to 3.16) 3.44 (2.53 to 4.61) 2.58 (1.98 to 3.30) Myocardial
infarction
1.11 (0.33 to 3.01) 1.38 (0.57 to 3.03) 2.74 (1.01 to 6.91) 0.89 (0.44 to 1.66) 2.38 (1.27 to 4.30) 1.42 (0.98 to 1.96) Stent thrombosis
Target revascularisation:
3.25 (1.77 to 5.71) 3.18 (1.95 to 4.97) 7.52 (4.97 to 11.29) 3.03 (2.06 to 4.40) 5.92 (4.30 to 8.05) 3.25 (2.57 to 4.04) Lesion
4.59 (2.45 to 8.36) 4.93 (3.27 to 7.43) 7.93 (5.11 to 12.19) 4.30 (3.11 to 5.87) 7.05 (5.21 to 9.41) 4.91 (4.07 to 5.86) Vessel
SES=sirolimus eluting stent; PES=paclitaxel eluting stent; EES=everolimus eluting stent; ZES-E=Endeavor zotarolimus eluting stent; BP-BES=biodegradable
polymer biolimus eluting stent; ZES-R=Resolute zotarolimus eluting stent.
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RESEARCHFigures
Fig 1 Evidence network among stents included in meta-analysis. Links between stent types represent direct (lines) comparison
studies. Nodes denote stent type; thickness of link indicates number of direct comparisons. SES=sirolimus eluting stent;
PES=paclitaxel eluting stent; EES=everolimus eluting stent; ZES-E=Endeavor zotarolimus eluting stent;
BP-BES=biodegradable polymer biolimus eluting stent; ZES-R=Resolute zotarolimus eluting stent
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RESEARCHFig 2 Pooled odds ratio and 95% credible intervals determined by network meta-analysis for mortality. BP=biodegradable
polymer; E=Endeavor; R=Resolute
Fig 3 Pooled odds ratio and 95% credible intervals determined by network meta-analysis for myocardial infarction.
BP=biodegradable polymer; E=Endeavor; R=Resolute
Fig 4 Pooled odds ratio and 95% credible intervals determined by network meta-analysis for definite or probable stent
thrombosis. BP=biodegradable polymer; E=Endeavor; R=Resolute
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RESEARCHFig 5 Pooled odds ratio and 95% credible intervals determined by network meta-analysis for target lesion revascularisation.
BP=biodegradable polymer; E=Endeavor; R=Resolute
Fig 6 Pooled odds ratio and 95% credible intervals determined by network meta-analysis for target vessel revascularisation.
BP=biodegradable polymer; E=Endeavor; R=Resolute
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6530 doi: 10.1136/bmj.f6530 (Published 6 November 2013) Page 16 of 17
RESEARCHFig 7 Posterior probabilities of different risk thresholds (odds ratios) for each stent compared with sirolimus eluting stent
(reference treatment). Curves can be used to examine overall safety and efficacy profile of specific DES compared with
reference treatment sirolimus-ES (SES) (identity line=unit value); improved safety and efficacy profiles indicated by highest
leftward shift of curve, as shown with Resolute zotarolimus-ES (ZES-R) and everolimus-ES (EES) with regard to mortality
and myocardial infarction; curves allow inferences to extract probabilities of specific risk thresholds corresponding to minimal
odds ratio compared with sirolimus-ES as reference treatment. For example, compared with sirolimus-ES, there is probability
of 65% that Resolute zotarolimus-ES reduce odds of mortality by at least 20% corresponding to odds ratio of 0.80; conversely,
this probability is estimated to be close to 0% with biodegradable polymer biolimus-ES (BP-BES), meaning no additional
mortality benefit provided by biodegradable polymer biolimus-ES compared with sirolimus-ES; there is a probability of 56%
and 49%, respectively, that Resolute zotarolimus-ES and everolimus-ES reduced odds of myocardial infarction by at least
10% corresponding to odds ratio of 0.90 but this probability is estimated close to 0% with biodegradable polymer biolimus-ES,
meaning no additional myocardial infarction benefits provided by biodegradable polymer biolimus-ES compared with
sirolimus-ES (reference treatment). PES=paclitaxel eluting stent; ZES-E=Endeavor zotarolimus-ES
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